Atrix/Fujisawa submit Aczone

This article was originally published in Pharmaceutical Approvals Monthly

15 Sep 2004
News

Executive Summary

Atrix' Aczone (dapsone 5% gel) could clear FDA by mid-2005. Atrix and development partner Fujisawa submitted the NDA for the topical acne treatment Aug. 31 for standard review. Dapsone is currently available only as an oral tablet "due to the compound's water insolubility," Atrix says. Aczone (formerly Atrisone) employs Atrix' proprietary solvent microparticle delivery technology. Aczone is also in early clinicals for treatment of rosacea...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS002640

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS002640

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Atrix/Fujisawa submit Aczone

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert